Review decision – April 2018
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326).
Overall, no relevant new evidence was identified that would change the existing recommendations in TA326.
Generic versions of imatinib are now available but do not include an indication for adjuvant treatment of gastrointestinal stromal tumour (GIST). The company has confirmed that no changes in marketing authorisation are anticipated and there have not been any changes to the price.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently TA326 will move to the ‘static list’ of technology appraisals.
This page was last updated: 23 April 2018